Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312815 | 0.84 | KCNH2 (0.59) | POLBKCNH2HTR1ADRD2DRD4 | |
| SCHEMBL4002253 | 0.84 | ALDH1A1 (0.55) | POLBKCNH2PLD1ALDH1A1KDM4E | |
| SCHEMBL1307606 | 0.84 | POLB (0.55) | POLBKCNH2PLD1ALDH1A1KDM4E | |
| SCHEMBL313359 | 0.83 | KCNH2 (0.66) | POLBKCNH2HTR1ADRD2DRD4 | |
| SCHEMBL13711971 | 0.81 | KCNH2 (0.71) | POLBKCNH2ALDH1A1HTR1ADRD2 | |
| SCHEMBL29857922 | 0.80 | PLD1 (0.73) | POLBKCNH2PLD1ALDH1A1KDM4E | |
| SCHEMBL21353591 | 0.80 | — | — | |
| SCHEMBL15800694 | 0.80 | PLD1 (0.73) | POLBKCNH2PLD1ALDH1A1KDM4E | |
| SCHEMBL926857 | 0.80 | MEN1 (0.50) | POLBALDH1A1KDM4EMAPTHTR1A | |
| SCHEMBL23252409 | 0.78 | POLB (0.59) | POLBKCNH2PLD1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820818-B2 | Heteroaryl nitrile derivatives | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| CN-100509813-C | Hetereoaryl nitrile derivative | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| US-7544688-B2 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2009-06-09 | — | — | US | disclosed |
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1678613-A | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2005-10-05 | — | — | CN | disclosed |
| EP-1537111-A1 | HETEREOARYL NITRILE DERIVATIVES | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020441-A1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| US-4180574-A | Certain ovicidal piperazines | ABBOTT LABORATORIES (US) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | CTSK, CTSS, CTSZ | POLB 4068/4885KCNH2 2937/4885PLD1 4226/4885 |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | CTSK, CTSZ, CTSE | POLB 4536/4885KCNH2 2008/4885PLD1 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.